Skip to main content
J

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 3 across all filing types
Latest filing 2026-04-14 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于金陵药业股份有限公司2025年度持续督导定期现场检查报告
Audit Report / Information Classification · 1% confidence The document is a detailed onsite inspection report (“现场检查报告”) prepared by the sponsor (中信证券) for the ongoing supervision of a listed company, covering governance, internal control, disclosure, use of funds, performance checks, etc. It is not a simple announcement or a summary; it is the full supervisory/audit‐style report itself. This aligns with the Audit Report / Information category (AR) for standalone audit or regulatory inspection reports outside of full annual/quarterly filings.
2026-04-14 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2025年度保荐工作报告
Regulatory Filings Classification · 0% confidence The document is a 2025 annual sponsorship work report (“保荐工作报告”) prepared by the sponsor (CITIC Securities) on its regulatory review, supervision, and compliance actions for Jinling Pharmaceutical. This is not an earnings release, annual report, management discussion, proxy statement, or other specific category. It is a required regulatory submission by the sponsor but does not match any narrowly defined filing type. Hence it defaults to the general Regulatory Filings category.
2026-04-14 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2023年向特定对象发行股票持续督导保荐总结报告书
Share Issue/Capital Change Classification · 1% confidence The document is a detailed sponsor (保荐人) summary report (“持续督导保荐总结报告书”) concerning Jinling Pharmaceutical’s 2023 directed A-share issuance: it spells out the number of shares, issue price, net proceeds, regulatory approvals and continuous supervision work. This falls under share issuance/capital change filings rather than an earnings release, management discussion, or annual report. Therefore the best fit is Share Issue/Capital Change (SHA).
2026-04-14 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.